Table 1. – Comparison of clinical-laboratory characteristics and outcomes between elderly and non-elderly individuals with IE, January 2006 to September 2019.

Variable/proportion in percentage (%)	Elderly (n=93)	Non-elderly (n=266)	p-value
Male gender	72	60.2	p=0.04
Acute evolution	63.3	46.8	p=0.019
Hospital-acquired infection	39.8	24.5	p=0.005
Non-hospital healthcare setting acquired infection	10.8	7.2	p=0.285
Fever	88.2	94.7	p=0.034
New regurgitating murmur	48.8	60.4	p=0.064
Embolic events	35.2	56.9	p<0.001
Embolic events for CNS	17.2	29.1	p=0.025
Splenomegaly	10.5	26.5	p=0.002
Enterococci	20.4	7.5	p<0.001
Viridans group streptococci	16	26	p=0.047
Staphylococcus aureus	12.9	10.5	p=0.531
Rheumatic valve disease	20.2	37.7	0.002
Congenital cardiopathy	1.1	18	<0.001
Valve prosthesis*	25.7	11.8	0.006
SAH	72.9	39.2	<0.001
DM	16.1	10.2	0.123
Dyslipidemia	35.0	14.8	<0.001
Atrial fibrillation	26.1	13.2	0.004
Previous HF	53.3	35.7	0.003
COPD	10.9	2.7	0.002
CAD	31.5	6.1	<0.001
CVD	10.8	4.9	0.047
PM	20.4	8.3	0.002
CKD	27.5	17.7	0.044
Hemodialysis	7.5	7.1	0.902
Neoplasia	12.9	3.9	0.002
Previous HS	52.7	32.2	<0.001
PCI	10.9	3.4	0.006
CABG	16.2	2.3	<0.001
ASA use	24.4	5.9	<0.001
Warfarin use	24.4	18.1	0.222
Surgical indication for IE	81.7	88.7	p=0.085
Mechanical ventilation**	30.3	18	p=0.015
Inotropic use**	33.7	21.8	p=0.028
In-hospital death	43.0	18.1	<0.001

CNS: central nervous system; SAH: systemic arterial hypertension; DM:diabetes mellitus; HF: heart failure; COPD: chronic obstructive pulmonary disease; CAD: coronary artery disease; CVD: cerebrovascular disease; PM: pacemaker; CKD: chronic kidney disease; HS: heart surgery; PCI: percutaneous coronary interventions; CABG: coronary artery bypass graft; ASA: acetylsalicylic acid; *valve prosthesis with more than 1 year of insertion; ** in the preoperative period of valve replacement for IE.